The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
PRAGMATICA-LUNG (SWOG S2302): A prospective, randomized study of ramucirumab plus pembrolizumab versus standard of care for participants previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer.
 
Konstantin Dragnev
Research Funding - Amgen (Inst); Daiichi Sankyo/Astra Zeneca (Inst); G1 Therapeutics (Inst); Io Therapeutics (Inst); Merck (Inst); Molecular Templates (Inst); Novartis (Inst); Roche/Genentech (Inst)
 
Mary Redman
No Relationships to Disclose
 
Karen Reckamp
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Lilly; Genentech; GlaxoSmithKline; Janssen Oncology; Merus; Novartis; Novocare; Pfizer
Research Funding - Blueprint Medicines; Daiichi Sankyo/Astra Zeneca (Inst); Elevation Oncology (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst)
 
Maya Khalil
Research Funding - Abbvie (Inst); Advenchen Laboratories (Inst); Amgen (Inst); Arcus Biosciences (Inst); Artios (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Cantargia AB (Inst); Caris Life Sciences (Inst); DynamiCure Biotechnology (Inst); Exelixis (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Guardant Health (Inst); Henlius (Inst); Henlius (Inst); Janssen (Inst); Johnson & Johnson/Janssen (Inst); Kronos (Inst); Lilly (Inst); Loxo/Lilly (Inst); Lucence (Inst); Merck (Inst); National Cancer Institute (Inst); NGM Biopharmaceuticals (Inst); Nitto BioPharma (Inst); Numab (Inst); Orum Therapeutics (Inst); Relay Therapeutics (Inst); Seagen (Inst); Spectrum Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TopAlliance BioSciences Inc (Inst); Xencor (Inst); Xencor (Inst)
 
Brian Henick
Honoraria - DAVA Oncology; OncLive/MJH Life Sciences
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech/Roche; IDEAYA Biosciences; Jazz Pharmaceuticals; Regeneron; Sorrento Therapeutics; Synthekine
Research Funding - Genentech/Roche (Inst); Johnson & Johnson/Janssen (Inst); NexImmune (Inst); Stand Up 2 Cancer (Inst); V Foundation (Inst)
 
James Moon
No Relationships to Disclose
 
Pasarlai Ahmadzai
No Relationships to Disclose
 
Michael LeBlanc
Consulting or Advisory Role - Agios
 
Daniel Carrizosa
Consulting or Advisory Role - Boehringer Ingelheim; Coherus Biosciences; Curio Science; Targeted Oncology
Speakers' Bureau - Bristol Myers Squibb; OncLive/MJH Life Sciences; PER
Research Funding - Bicara Therapeutics (Inst); Elevation Oncology (Inst); Merck (Inst); Scorpion Therapeutics (Inst); Takeda (Inst)
 
Paul Hesketh
Consulting or Advisory Role - UpToDate
 
Ellen Sigal
Stock and Other Ownership Interests - EQRx; GRAIL
Consulting or Advisory Role - EQRx; GRAIL
Travel, Accommodations, Expenses - AstraZeneca
 
Jeff Allen
No Relationships to Disclose
 
Andreas Saltos
Honoraria - MJH Life Sciences; MJH Life Sciences (I)
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Daiichi Sankyo/Astra Zeneca; Janssen; Lilly; Pfizer
Research Funding - AstraZeneca (Inst); BioAtla (Inst); Daiichi Sankyo (Inst); Genentech (Inst); Genmab (Inst); Janssen (Inst); Lilly (Inst); Memgen (Inst); Mersana (Inst); NGM Biopharmaceuticals (Inst); Novartis (Inst); Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - Dava Oncology
 
Bryan Faller
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Boehringer Ingelheim; Celgene; EB SQUIBB; Eisai; Genentech; Lilly; Merck; Novartis; Takeda
 
Roy Herbst
Leadership - American Association for Cancer Research; Friends of Cancer Research; IASLC; Immunocore; Junshi Pharmaceuticals; Society for Immunotherapy of Cancer; SWOG
Stock and Other Ownership Interests - Bolt Biotherapeutics; Checkpoint Therapeutics; Immunocore; Normunity
Consulting or Advisory Role - Abbvie; Amgen; ArriVent Biopharma; AstraZeneca; Bristol-Myers Squibb; Candel Therapeutics; Catalym; Checkpoint Therapeutics; Cybrexa Therapeutics; Genentech/Roche; Gilead/Forty Seven; I-Mab; Janssen; Junshi Pharmaceuticals; Lilly; Mediflix; Merck; NEUVOGEN; NextCure; Normunity; Novartis; Pfizer; Regeneron; Roche; Sanofi
Research Funding - AstraZeneca; Genentech/Roche; Lilly; Merck
Travel, Accommodations, Expenses - American Cancer Society; IASLC; SWOG
 
Charles Blanke
No Relationships to Disclose
 
Jhanelle Gray
Honoraria - AstraZeneca; Blueprint Medicies; Daiichi Sankyo, Inc; EMD Serono/Merck; Flatiron Health; Gilead Sciences; Gilead Sciences; IDEOlogy Health; Janssen Scientific Affairs; Jazz Pharmaceuticals; Loxo; Merck; Merck; Novartis; OncoCyte; Pfizer; Regeneron; Spectrum ODAC; Takeda; Triptych Health Partners
Consulting or Advisory Role - Abbvie; AstraZeneca; Blueprint Meicines; Daiichi Sankyo/UCB Japan; EMD Serono-Merck KGaA; Flatiron Health; Gilead Sciences; IDEOlogy Health; Janssen Scientific Affairs; Jazz Pharmaceuticals; Loxo; Merck; Novartis; OncoCyte Biotechnology Company; Pfizer; Regeneron; Spectrum Pharmaceuticals; Takeda; Triptych Health Partners
Research Funding - Array BioPharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech (Inst); Gilead Services (Inst); Lilly (Inst); Ludwig Institute for Cancer Research (Inst); Merck (Inst); Novartis (Inst); Panbela Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - Abbvie; OncoCyte; Spectrum Pharmaceuticals